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Abstract 
Background: The mouse protein Fv1 is a factor that can confer resistance to retroviral infection. The two major 
Fv1 alleles from laboratory mice, Fv1n and Fv1b, restrict infection by different murine leukaemia viruses (MLVs). Fv1n 
restricts B-tropic MLV, but not N-tropic MLV or NB-tropic MLV. In cells expressing Fv1b at natural levels, only N-MLV is 
restricted, however restriction of NB-MLV and partial restriction of B-MLV were observed when recombinant Fv1b was 
expressed from an MLV promoter in Fv1 null Mus dunni tail fibroblast cells. To investigate the relationship between 
expression level and restriction specificity we have developed new retroviral delivery vectors which allow inducible 
expression of Fv1, and yet allow sufficient production of fluorescent reporter proteins for analysis in our FACS-based 
restriction assay.
Results: We demonstrated that at concentrations close to the endogenous expression level, Fv1b specifically restricts 
only N-MLV, but restriction of NB-MLV, and to a lesser extent B-MLV, could be gained by increasing the protein level 
of Fv1b. By contrast, we found that even when Fv1n is expressed at very high levels, no significant inhibition of N-MLV 
or NB-MLV could be observed. Study of Fv1 mutants using this assay led to the identification of determinants for N/B 
tropism at an expression level close to that of endogenous Fv1n and Fv1b. We also compared the recently described 
restriction activities of wild mice Fv1 proteins directed against non-MLV retroviruses when expressed at different 
levels. Fv1 from M. spretus restricted N-MLV, B-MLV and equine infectious anaemia virus equally even at low concentra-
tions, while Fv1 from M. macedonicus showed even stronger restriction against equine infectious anaemia virus than 
to N-MLV. Restriction of feline foamy virus by Fv1 of M. caroli occurred at levels equivalent to MLV restriction.
Conclusions: Our data indicate that for some but not all Fv1 proteins, gain of restriction activities could be achieved 
by increasing the expression level of Fv1. However such a concentration dependent effect is not seen with most Fv1s 
and cannot explain the recently reported activities against non-MLVs. It will be interesting to examine whether over-
expression of other capsid binding restriction factors such as TRIM5α or Mx2 result in novel restriction specificities.
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Background
A lengthy period of coevolution between retroviruses 
and their hosts has resulted in the emergence of numer-
ous host defence mechanisms, as well as viral counter-
measures. These include a number of factors such as 
Fv1, Trim5α, Trim5Cyp and Mx2 that restrict infection 
through interaction with the retroviral cores [1–4]. Cap-
sid targeting domains of these antiviral proteins define 
their restriction specificities [5–14]. They have evolved 
under strong positive selection [10, 15–18], most likely 
through exposure to endogenous or exogenous retro-
viruses [8, 15, 19–22]. The study of the mechanisms of 
restriction is important not only for understanding deter-
minants of viral tropism and species barriers, but also 
might provide opportunities for the exploitation of these 
host defence proteins in novel antiretroviral therapies 
[23, 24].
Fv1 was first described in the early 1970s as a gene 
controlling susceptibility of mice to murine leukaemia 
virus (MLV) [25]. There are two major alleles [26] within 
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inbred laboratory mice, Fv1n and Fv1b. Fv1n is present 
in NIH-Swiss mice, which are permissive to infection 
by N-tropic MLV (N-MLV), but resistant to infection by 
B-tropic MLV (B-MLV). In contrast, Fv1b is expressed 
in BALB/c mice, which are susceptible to infection by 
B-MLV but not N-MLV [27, 28]. NB-tropic MLVs (NB-
MLVs) such as Moloney MLV can infect cells carrying 
either Fv1 allele [29]. The MLV capsid (CA) protein was 
found to be the target of Fv1 [30, 31], with residue 110 
being the major determinant controlling N versus B tro-
pism of MLV [32], while other positions of CA specify 
NB tropism [7, 30]. Although the precise mechanism 
of Fv1 restriction is not known, it has been shown that 
Fv1 blocks at a step after reverse transcription but before 
integration [33, 34], possibly by preventing the nuclear 
entry of viral DNA [35]. The Fv1 protein consists of two 
structural domains: an N-terminal domain (Fv1NTD) 
and a C-terminal domain (Fv1CTD), joined by a flexible 
linker [36]. The Fv1NTD, which contains an extended 
coiled-coil region, forms an antiparallel dimer [36, 37] 
while the Fv1CTD is believed to be the capsid-targeting 
domain [5–7, 37]. Fv1n and Fv1b differ only at 3 sites, 
amino acid (aa) 358, aa 399 and the C-terminus region, 
all within Fv1CTD [38]. Fv1n encodes K358, V399 and a 
short 3aa C-terminus, while Fv1b has E358, R399 and a 
long 22aa C-terminus [38]. Normal levels of Fv1 are low 
[39] and restriction can be overcome by pre-exposure to 
MLV [40]. Despite this Fv1 can represent a substantial 
barrier to MLV-induced leukemogenesis [41].
To study the determinants of Fv1 restriction specific-
ity, we developed a two colour FACS assay [5] employ-
ing the Mus dunni tail fibroblast (MDTF) cell line, which 
lacks functional Fv1 due to a premature stop codon in 
its Fv1 allele [21, 42]. Transduction of MDTF cells with 
the retroviral delivery vector LxIG-Fv1 (Fig.  1a) at low 
multiplicities of infection (MOI) allows the expression 
of both Fv1 and EGFP in a subpopulation of cells [5]. A 
bicistronic vector mRNA is constitutively transcribed 
from the integrated proviral vector genome, allowing the 
CAP-dependent translation of Fv1 and IRES-dependent 
translation of EGFP [43]. Mixed populations of cells are 
then infected with VSV-G packaged MLV tester viruses 
with Gag and Pol derived from N-MLV, B-MLV or NB-
MLV, and a genome that allows the expression of EYFP in 
infected cells. By comparing the infectivity of EYFP tester 
virus in the EGFP-positive population with that in the 
EGFP-negative population, the restriction activity due to 
Fv1 expression could be measured.
Our initial study showed that the expression of recom-
binant Fv1n in MDTF cells led to restriction of B-MLV 
by more than tenfold but no inhibition against N-MLV 
and NB-MLV [5]. However, although previous studies 
showed that cells naturally expressing endogenous Fv1b 
only restrict N-MLV but not NB-MLV or B-MLV [29], 
the expression of recombinant Fv1b in MDTF cells led to 
restriction of NB-MLV by fivefold, inhibition of B-MLV by 
30 %, in addition to the restriction of N-MLV by more than 
tenfold [5]. Comparison of Fv1 protein levels in transduced 
MDTF with cell lines which endogenously express Fv1n 
(N-3T3) or Fv1b (B-3T3) by semi-quantitative western 
blot suggested that the Fv1 expression level in transduced 
MDTF cells far exceeded those in cells naturally express-
ing Fv1 [39]. The expression of recombinant Fv1b in B-3T3 
cells using the LxIG-Fv1 vector also led to stronger restric-
tion of all MLVs [5]. These observations led to the idea that 
overexpression of Fv1 might reveal additional restriction 
activities not seen with endogenous levels of Fv1.
Various mutants of Fv1n and Fv1b were studied using 
the two colour assay, including “mix-and-match” mutants 
that contain different combinations of sequence from 
Fv1n or Fv1b at the 3 variable sites [5], mutants with ala-
nine introduced at one or more of the variable sites [6], 
as well as mutants with the truncation of C-terminus 
from Fv1n or Fv1b [6]. Among the three sites, position 358 
appears to have the strongest effect in determining N/B 
tropism [5, 6]. All mutants with K358 from Fv1n restrict 
B-MLV but not N-MLV [5, 6]. In contrast all mutants with 
E358 from Fv1b or A358 restrict N-MLV, and also restrict 
B-MLV as long as it does not possess the Fv1b C-terminus 
[5, 6]. All mutants that restrict NB-MLV contain R399 
from Fv1b [5, 6]. While these data suggested that residues 
at all three variable sites could influence the restriction 
specificities towards MLVs, it is not known whether all 
of the restriction activities could still be observed when 
the Fv1 mutants were expressed at a level closer to the 
endogenous levels of Fv1n and Fv1b, or whether the deter-
minants for MLV tropism at low, endogenous levels are 
different from those following overexpression.
The presence of a common retroviral motif, the Major 
Homology Region (MHR) within the Fv1 gene was in 
part responsible for the suggestion that Fv1 originated as 
part of the Gag protein of a murine endogenous retrovi-
rus MERV-L [38, 44], and this MHR motif was found to 
be essential for MLV restriction and capsid binding activ-
ities in Fv1n [1, 6]. Phylogenetic analysis of wild mice Fv1 
sequences suggested that the Fv1 was inserted to ances-
tor of Mus species about 4–7 million years ago [8, 15, 21]. 
Studies of some of these sequences in MDTF cells trans-
duced with the LxIY-Fv1 vector has led to the identifica-
tion of novel restriction activities directed against MLV, 
as well as the lentivirus equine infectious anaemia virus 
(EIAV) and the spumavirus feline foamy virus (FFV) [8]. 
Many of the Fv1 specificity determinants identified were 
found in residues which showed evidence for positive 
selection [15], suggesting that some of these restriction 
activities of Fv1 was selected for, possibly from pressure 
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during prior exposure to retroviruses [8]. It is therefore 
of considerable interest to know whether overexpression 
might contribute to these novel activities.
To explore the relationship between expression levels 
and restriction specificity we set out to develop new ret-
roviral delivery vectors which allow inducible expression 
of Fv1 compatible with our two-colour FACS assay for 
measurement of retroviral infectivity. This would allow us 
to ask (1) whether restriction factor overexpression inevi-
tably leads to novel patterns of restriction and (2) whether 
overexpression was required for the new specificities we 
had observed in different species of mice [8]. This paper 
reports the development and use of such a system, in 
combination with the quantitation of Fv1 protein levels, 
to examine the restriction activities shown by different 
Fv1 alleles at different concentrations of restriction factor.
Results
Novel vectors to study restriction activities of Fv1 
at different expression levels
To examine the relationship between Fv1 expression 
levels and restriction specificity, we wanted to study the 
Fig. 1 Retroviral vectors used for expression of Fv1. a Schematic diagrams showing the plasmids for the previously described non-inducible 
bicistronic retroviral vectors, LxIG-Fv1 and LxIY-Fv1. After provirus formation, transcription of bicistronic mRNA is driven by the MLV U3 promoter, 
and translation of Fv1 is initiated at the 5′ CAP while the translation of the fluorescent protein is initiated from an EMCV IRES element. b Schematic 
diagrams showing the plasmids for the novel inducible bicistronic retroviral vectors used in this study. After integration into cells expressing the 
rtTA3 transactivator, the transcription level of bicistronic RNA driven by the inducible TRE3G promoter is dependent on the concentration of added 
doxycycline. The translation of the fluorescent protein is initiated at the 5′ CAP. For TGIx-Fv1 and TYIx-Fv1, the translation of Fv1 is initiated from 
an EMCV IRES. For TGx-Fv1 and TYx-Fv1, the Fv1 ORF is placed downstream to that of the fluorescent protein, and is most likely translated by a 
ribosome re-initiation mechanism. CMV, Cytomegalovirus immediate early promoter; R, repeated element; U5, unique 5′ element; U3, unique 3′ 
element; ΔU3, U3 region with deletion in enhancer sequence; Ψ, packaging signal; B1, Gateway cloning attB1 site; B2, Gateway cloning attB2 site; 
TRE3G, doxycycline-inducible TRE3G promoter. c FACS plots showing the separation of GFP+ and GFP− populations by FACS analysis in MDTF-R18 
cells transduced with LxIG-Fv1b, TGx-Fv1b and TGIx-Fv1b retroviral vectors. Cells transduced with the inducible vectors were treated with 10 μg/mL 
doxycycline for 24 h prior to analysis
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restriction of different MLVs at different concentrations 
of Fv1n and Fv1b, including both endogenous and overex-
pression levels, using our two-colour FACS-based restric-
tion assay [5]. We initially attempted to develop vectors 
allowing the expression of Fv1 under its natural promoter 
in MDTF cells, so that the restriction activity of Fv1 at 
endogenous levels could be studied. We constructed a 
self-inactivating (SIN) retroviral vector in which the nat-
ural promoter of Fv1 drives the transcription of a bicis-
tronic mRNA with the Fv1 ORF, followed by the EMCV 
IRES and finally the EYFP ORF. However, the low level 
of transcription driven by the natural Fv1 promoter does 
not provide sufficient separation between transduced and 
untransduced cell populations for a 2-colour FACS assay.
We therefore set out to devise an inducible expres-
sion system, using components of the Tet-On 3G system 
(Clontech) [45, 46] and designed new MLV-based SIN 
vectors for doxycycline-inducible expression of Fv1 and 
either EGFP or EYFP (Fig.  1b). Promoters used in dox-
ycycline-inducible expression system often suffer from 
“leaky expression” due to constitutive transcription activ-
ity from the inducible promoter in the absence of doxycy-
cline. Although the PTRE3G promoter from the Tet-On 3G 
system is less leaky than previous doxycycline-inducible 
promoters [46, 47], even a low level of transcription may 
be sufficient to drive Fv1b expression above its endog-
enous level [39]. We therefore modified both transcrip-
tional and translational signals of our previous retroviral 
vectors, to minimise uninduced Fv1 expression and to 
maximise the expression level of the reporter gene allow-
ing sufficient separation for FACS analysis.
Previous studies using reporter genes have found that 
in a bicistronic mRNA with the arrangement of ORF1-
IRES-ORF2, the translation of the second ORF is often 
less efficient than the first ORF [48, 49]. Moreover, an 
eightfold lower translation efficiency of the second ORF 
compared to the first ORF has been reported when an 
attenuated form of EMCV IRES is used [49]. We there-
fore constructed the TGIx-Fv1 vector, in which the 
PTRE3G promoter drives the transcription of a bicistronic 
EGFP-IRES-Fv1 mRNA (Fig.  1b). To achieve optimal 
translation of EGFP through a CAP-dependent initia-
tion mechanism we placed the EGFP close to the 5′ CAP 
structure of the mRNA, and included a strong Kozak 
sequence (GCCGCCATGG) for the EGFP ORF [50]. 
Translation of Fv1 was attenuated by using an IRES with 
a suboptimal A7 sequence at the bifurcation loop [49] 
and by including a 71nt sequence (mostly from the Gate-
way cloning attB1 recombination site) between the IRES 
and the Fv1ORF.
We also explored the possibility of reducing the trans-
lation of Fv1 by using an upstream ORF in the absence 
of a functional IRES. There are many examples in which 
the translation of a downstream ORF is inhibited by the 
presence of one or more upstream ORFs [51–53]. Of 
these, most could be explained by an inefficient ribo-
some reinitiation mechanism, in which following trans-
lational termination of the first ORF, the 40S ribosome 
remains bound to the mRNA and continues scanning it 
until the reinitiation of translation at the start codon of 
the downstream ORF [53]. In a study involving IRES-
free bicistronic mRNAs each with two reporter genes, 
the expression level of the second ORF was reported to 
be up to 1000-fold lower that of the first ORF [48]. Aim-
ing to provide further translational attenuation of Fv1, 
we therefore constructed the IRES-free TGx-Fv1 vector, 
in which the EGFP ORF is placed upstream of the Fv1 
ORF (Fig. 1b). Since ribosome re-initiation is much less 
efficient than IRES-mediated initiation, we expected the 
TGx-Fv1 vector to promote an even lower Fv1 expression 
level than the TGIx-Fv1 vector in the absence of doxycy-
cline, while retaining optimal expression of EGFP with 
both vectors in the presence of doxycycline by a CAP-
dependent initiation mechanism. EYFP-expressing ver-
sions of the inducible vectors, TYIx-Fv1 and TYx-Fv1, 
were constructed in a similar fashion (Fig. 1b).
 We tested the new inducible vectors in the MDTF-
R18 cell line, which constitutively expresses the rtTA3 
transactivator [45]. It was derived from MDTF cells 
transduced with a lentiviral vector encoding rtTA3 and 
blastocidin resistance and selected from a large num-
ber of antibiotic resistant clones for strong doxycycline 
induction of the PTRE3G promoter and minimal leakiness 
in the absence of doxycycline (Additional file  1). How-
ever, initial titration experiments showed that TGx-Fv1 
transduced MDTF-R18 cells required induction for 24 h 
with at least 100 ng/mL of doxycycline to allow the FACS 
separation of transduced and untransduced populations 
(Additional file  2). We therefore modified our standard 
Fv1 restriction assay [5] accordingly. Fv1 expression in 
delivery virus (TGx-Fv1 or TGIx-Fv1) transduced cells 
was induced with varying concentrations of doxycycline 
(0–1000  ng/mL) for 24  h before infection with EYFP 
tester virus. 24 h after tester virus infection, during which 
time Fv1-mediated restriction would be predicted to 
occur, 10 µg/mL of doxycycline was added to all samples 
to ensure a sufficient EGFP expression for the two-colour 
FACS assay. Using this approach, the GFP separation of 
cells transduced with either of the inducible vectors was 
comparable to that of the non-inducible vector pLxIG 
(Fig.  1c). When doxycycline was first added 24  h after 
the infection of N-MLV tester virus, no restriction by 
Fv1b could be detected (Additional file 3), supporting the 
hypothesis that any Fv1 produced after 24hpi does not 
Page 5 of 17Li et al. Retrovirology  (2016) 13:42 
interact with the tester virus. This assay now allows us to 
compare the infectivity of EYFP tester virus in the Fv1-
expressing transduced population to that in the control 
untransduced population, permitting the measurement 
of Fv1-specific inhibition independent of non-specific 
effects such as the presence of doxycycline.
MLV restriction activities of Fv1n and Fv1b at different 
expression levels
To test the utility of these novel inducible vectors in 
restriction assays, we measured the MLV restriction 
activities of Fv1n and Fv1b using N-MLV, B-MLV and 
NB-MLV with TGIx-Fv1, TGx-Fv1 and LxIG-Fv1 vec-
tors (Table  1). As expected, the results from restriction 
studies using the LxIG-Fv1 vector in MDTF-R18 cells 
were similar to those reported previously in MDTF cells 
[5]. At the same time we tested the restriction activities 
seen when the TGx-Fv1 and TGIx-Fv1 vectors in cells 
treated with or without 1000 ng/mL doxycycline for 24 h 
before infection (Table 1). When using the TGx-Fv1 vec-
tor in the absence of doxycycline, neither Fv1n nor Fv1b 
demonstrated any detectable inhibition of MLV. The 
complete lack of inhibition suggested that with this vec-
tor in the absence of doxycycline both Fv1n and Fv1b 
were expressed at lower levels than seen in NIH-3T3 
or BALB-3T3 (endogenous levels). When treated with 
doxycycline, the TGx vector-expressed Fv1n restricted 
B-MLV by fourfold and the Fv1b restricted N-MLV by 
fivefold. Weak inhibition of NB-MLV by Fv1b by about 
20  % was also observed under these conditions. When 
using the TGIx-Fv1 vector in the absence of doxycycline, 
partial restriction could be detected with both Fv1n and 
Fv1b, suggesting that the expression levels of Fv1n and 
Fv1b under these conditions are below their endogenous 
levels, but substantially higher that in TGx-Fv1 with-
out doxycycline. When treated with doxycycline, the 
restriction activities against B-MLV and against N-MLV 
by TGIx-Fv1 appeared substantially stronger than TGx-
Fv1, but still weaker than LxIG-Fv1. At this level, partial 
restriction of NB-MLV by Fv1b was clearly observed. 
Therefore, across the five induction levels, the strength 
of each MLV restriction activity could be arranged, from 
the weakest to the strongest, in the order of TGx-Fv1 −
Dox  <  TGIx-Fv1 −Dox  <  TGx-Fv1 +Dox  <  TGIx-Fv1 
+Dox < LxIG-Fv1.
Since the difference in degree of restriction is most 
likely due to differences in Fv1 expression levels, we next 
attempted to compare the Fv1 protein levels under these 
five conditions with the natural Fv1 levels in N-3T3 and 
B-3T3 cells in quantitative western blots (Fig.  2; Addi-
tional file  4). The expression level of Fv1n in N-3T3 
cells was threefold higher than that of Fv1b in B-3T3 
cells. The greater mobility of Fv1n compared to Fv1b 
can be explained by a 19 amino acid difference in length 
between the two proteins [38]. The LxIG-Fv1 vector 
gave around 55-fold overexpression of Fv1n and 30-fold 
overexpression of Fv1b. Overexpression of Fv1n and Fv1b 
were also observed with doxycycline treated TGIx-Fv1 
cells, although the expression levels were only about half 
of that seen with LxIG-Fv1. In both of these overexpres-
sion systems, the expression of Fv1n is 3–4 fold higher 
than that of Fv1b when the same vector and doxycycline 
concentration were used, presumably as a result of differ-
ing protein stability since the non-coding sequences in 
pairs of vectors are identical. The Fv1 protein levels with 
TGx-Fv1 −Dox, TGIx-Fv1 −Dox and TGx-Fv1 +Dox 
were much lower. In some cases, faint bands correspond-
ing to the molecular weight of Fv1 could be observed by 
fluorescent western blot. However, the weak fluorescent 
signals from these bands were almost indistinguishable 
from background noise, and cannot be quantified reli-
ably. Analysis is further complicated by the copy number 
Table 1 Restriction activity of Fv1n and Fv1b against MLVs at different expression levels
Table shows mean and standard deviation values calculated from three independent restriction experiments carried out in transduced MDTF-R18 cells. A lower 
restriction ratio indicates stronger inhibition by Fv1. We arbitrarily divide restriction activity into three levels; Full, shown in bolditalic (restriction ratio ≤0.3), Partial, 
indicated in italics (0.3 < ratio ≤ 0.7) and None (ratio > 0.7)
Vector TGx-Fv1 TGIx-Fv1 LxIG-Fv1
Dox (ng/mL) 0 1000 0 1000 0
Fv1n
 N-MLV 1.15 ± 0.07 1.16 ± 0.04 1.22 ± 0.11 1.13 ± 0.05 1.07 ± 0.03
 B-MLV 1.15 ± 0.09 0.24 ± 0.04 0.56 ± 0.01 0.14 ± 0.02 0.06 ± 0.01
 NB-MLV 1.17 ± 0.06 1.18 ± 0.04 1.21 ± 0.04 1.09 ± 0.06 1.08 ± 0.01
Fv1b
 N-MLV 1.02 ± 0.09 0.17 ± 0.01 0.45 ± 0.09 0.13 ± 0.01 0.07 ± 0.02
 B-MLV 1.13 ± 0.07 1.10 ± 0.06 1.12 ± 0.02 0.87 ± 0.01 0.63 ± 0.02
 NB-MLV 1.21 ± 0.04 0.79 ± 0.03 1.01 ± 0.07 0.35 ± 0.02 0.21 ± 0.03
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of the transduced Fv1—haploid when transduced at an 
MOI of 1 and diploid in N-3T3 and B-3T3 cells. Never-
theless, the western blot results confirmed that at a given 
doxycycline concentration, a lower Fv1 expression level 
can be seen using pTGx-Fv1 than TGIx-Fv1. Comparison 
of these data (Fig. 2; Table 1) with our previous analysis 
of restriction in N-3T3 and B-3T3 cells [5] suggests that 
natural Fv1 expression levels lie intermediate between 
those found with TGx-Fv1 +Dox and TGIx-Fv1 +Dox. 
Under these conditions Fv1b has little or no effect on 
B-MLV but significant restriction of NB-MLV.
MLV restriction activities at “superexpression” levels 
of Fv1n and Fv1b
While the overexpression of Fv1b using LxIG-Fv1 enables 
the restriction of NB-MLV and even partial restriction 
of B-MLV, the overexpression of Fv1n using LxIG-Fv1 
did not lead to even the slightest inhibition of N-MLV or 
NB-MLV. However it seemed possible that inhibition of 
N-MLV and NB-MLV by Fv1n might be observed at an 
expression level even higher than that by the LxIG-Fv1 
vector. We therefore set out to express Fv1 at “superex-
pression” levels by transducing MDTF-R18 cells with 
Fig. 2 Expression levels of Fv1n and Fv1b from inducible and non-inducible retroviral vectors. a Quantitative western blot analysis of Fv1 in N-3T3 
cells, B-3T3 cells, and in MDTF-R18 cells transduced with either non-inducible or inducible vectors expressing Fv1 (MOI 0.7). Fv1 was detected using 
an anti-Fv1 antibody and the LI-COR Odyssey infrared fluorescent western blot system. 1000 ng/mL doxycycline was added to culture media for 
induced samples. Quantities of Fv1 in lysate samples were interpolated from a standard curve generated using fluorescent signals from known 
quantities of purified Fv1NTD protein loaded on the same gel. Numbers under the blot indicate the quantities of Fv1 in each sample relative to 
that in the N-3T3 sample. b Quantities of Fv1 in transduced MDTF-R18 and B-3T3, relative to that of N-3T3. Data from Additional file 1 are shown as 
a grouped scatter plot. Mean values are represented by horizontal lines, while individual results are plotted as symbols: filled circle, endogenous Fv1 
from N-3T3 or B-3T3 cells; open square, TGx-Fv1 without dox; filled square, TGx-Fv1 with 1000 ng/mL dox; open triangle, TGIx-Fv1 without dox; filled 
triangle, TGIx-Fv1 with 1000 ng/mL dox; filled diamond, LxIG-Fv1 without dox
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the LxIG-Fv1 vector at high MOI’s. Such cells were then 
mixed with untransduced cells as internal controls, and 
infected with EYFP tester viruses for two colour restric-
tion assays. As control for non-specific effects of high 
provirus copy number unrelated to Fv1 expression e.g. 
EYFP overexpression, two control vectors were employed. 
The first contains the genome for the generation of EGFP 
tester virus, in which a CMV promoter drives the expres-
sion of EGFP only. The second, LxIG-Fv1n-AGG, is a 
mutated form of the LxIG-Fv1n vector in which the start 
codon of Fv1 ORF is changed from ATG to AGG to abol-
ish Fv1 expression, but still allow the expression of EGFP 
using the IRES. Although non-specific restriction was 
observed at MOI’s greater than ten (Fig.  3), in none of 
these experiments did LxIG-Fv1n exhibit stronger inhibi-
tion of N-MLV or NB-MLV than any of the control vec-
tors, suggesting that further increasing the concentration 
of Fv1n in cells does not enable the inhibition of N-MLV 
and NB-MLV by Fv1n. In addition no additional restric-
tion of B-MLV by Fv1b was seen at higher MOI’s.
Restriction studies of Fv1n and Fv1b mutants at different 
expression levels
Previous restriction studies using the LxIG-Fv1 vector 
on 6 “mix-and-match” mutants which harbour either 
Fv1n or Fv1b sequence at positions 358, 399 and at the 
C-terminus [5], and on Fv1n and Fv1b with truncation at 
the C-terminus [6], have showed that restriction specific-
ity against different MLVs appeared to be a combinato-
rial property of C-terminal Fv1 sequences, at least when 
present at overexpressed levels [5, 6]. We extended the 
studies of these mutants using the new inducible vectors, 
to ask whether the novel specificities revealed in those 
previous studies were dependent upon over expression, 
focussing our analysis on comparing the MLV restric-
tion activities of endogenous-like level of Fv1 (TGx-Fv1 
+Dox and TGIx-Fv1 +Dox) to that of overexpression 
levels (LxIG-Fv1). In all we tested three different viruses 
for restriction with eight different Fv1 constructs in addi-
tion to the parental Fv1n and Fv1b. Examining these 24 
combinations (Table 2) revealed that the majority resem-
bled the patterns seen with Fv1n; nine showed restriction 
profiles (profile A) closely resembling those seen for Fv1n 
against B-MLV while a further nine showed no effect at 
any Fv1 concentration like Fv1n and N-MLV (profile D). 
In four cases full restriction was observed but only at 
high Fv1 concentrations, resembling the effect of Fv1b on 
NB-MLV (profile B). Two hybrid Fv1s resembled Fv1b by 
giving partial restriction (by nnb and bb_ on N-MLV and 
B-MLV, respectively) at high concentrations (profile C).
Fig. 3 Restriction activity of various Fv1 at “superexpression” levels against different MLVs. Restriction of a N-MLV, b B-MLV and c NB-MLV in cells 
transduced at various MOIs with the LxIG-Fv1n vector (red squares), the LxIG-Fv1b vector (black circles), the LxIG-Fv1n-AGG mutant vector (green 
triangles) or the EGFP tester virus (purple diamonds). Dotted vertical lines indicate an MOI of 1
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Table 2 Restriction activity of various Fv1 mutants against MLVs at different Fv1 expression levels
We arbitrarily divide restriction activity into three levels; Full, shown in bolditalic (restriction ratio ≤0.3), Partial, indicated in italics (0.3 < ratio ≤ 0.7) and None 
(ratio > 0.7)
Table shows mean and standard deviation values calculated from three independent restriction experiments carried out in transduced MDTF-R18 cells. Data for Fv1n 
and Fv1b from Table 1
a Classification into groups of constructs with similar activity profiles. A. Full restriction; B. Full restriction only at elevated concentration; C. Partial restriction at high 
concentrations; D. No restriction. Full and partial restriction defined as in Table 1
Vector TGx-Fv1 TGIx-Fv1 TGx-Fv1 TGIx-Fv1 LxIG-Fv1 Activity profilea
Dox (ng/mL) 0 0 1000 1000 0
Fv1n
 N-MLV 1.15 ± 0.07 1.22 ± 0.11 1.16 ± 0.04 1.13 ± 0.05 1.07 ± 0.03 D
 B-MLV 1.15 ± 0.09 0.56 ± 0.01 0.24 ± 0.04 0.14 ± 0.02 0.06 ± 0.01 A
 NB-MLV 1.17 ± 0.06 1.21 ± 0.04 1.18 ± 0.04 1.09 ± 0.06 1.08 ± 0.01 D
Fv1b
 N-MLV 1.02 ± 0.09 0.45 ± 0.09 0.17 ± 0.01 0.13 ± 0.01 0.07 ± 0.02 A
 B-MLV 1.13 ± 0.07 1.12 ± 0.02 1.10 ± 0.06 0.87 ± 0.01 0.63 ± 0.02 C
 NB-MLV 1.21 ± 0.04 1.01 ± 0.07 0.79 ± 0.03 0.35 ± 0.02 0.21 ± 0.03 B
Fv1bbn
 N-MLV 0.97 ± 0.02 0.38 ± 0.04 0.17 ± 0.06 0.11 ± 0.00 0.06 ± 0.01 A
 B-MLV 1.10 ± 0.02 0.58 ± 0.10 0.29 ± 0.06 0.11 ± 0.02 0.07 ± 0.03 A
 NB-MLV 0.96 ± 0.08 0.33 ± 0.07 0.19 ± 0.04 0.08 ± 0.02 0.08 ± 0.02 A
Fv1nnb
 N-MLV 1.18 ± 0.06 1.09 ± 0.07 1.07 ± 0.07 0.72 ± 0.10 0.58 ± 0.04 C
 B-MLV 1.13 ± 0.09 0.76 ± 0.03 0.52 ± 0.03 0.14 ± 0.03 0.09 ± 0.02 A
 NB-MLV 1.15 ± 0.10 1.16 ± 0.06 1.07 ± 0.10 1.07 ± 0.13 1.07 ± 0.05 D
Fv1bnn
 N-MLV 1.14 ± 0.07 0.46 ± 0.01 0.18 ± 0.07 0.12 ± 0.02 0.09 ± 0.06 A
 B-MLV 1.20 ± 0.01 1.04 ± 0.04 0.93 ± 0.05 0.33 ± 0.03 0.12 ± 0.03 B
 NB-MLV 1.21 ± 0.12 1.09 ± 0.10 1.12 ± 0.06 1.02 ± 0.03 0.98 ± 0.05 D
Fv1nbb
 N-MLV 1.17 ± 0.04 1.17 ± 0.02 1.05 ± 0.07 1.01 ± 0.03 0.93 ± 0.07 D
 B-MLV 1.18 ± 0.04 0.81 ± 0.08 0.66 ± 0.03 0.12 ± 0.05 0.07 ± 0.02 A
 NB-MLV 1.15 ± 0.06 1.09 ± 0.05 1.12 ± 0.11 1.17 ± 0.07 1.10 ± 0.07 D
Fv1nbn
 N-MLV 1.20 ± 0.05 1.10 ± 0.03 1.12 ± 0.09 1.03 ± 0.07 1.02 ± 0.11 D
 B-MLV 1.12 ± 0.07 0.50 ± 0.04 0.23 ± 0.01 0.09 ± 0.02 0.08 ± 0.03 A
 NB-MLV 1.11 ± 0.02 0.62 ± 0.11 0.33 ± 0.05 0.12 ± 0.03 0.09 ± 0.02 A
Fv1bnb
 N-MLV 1.05 ± 0.08 0.56 ± 0.06 0.22 ± 0.03 0.10 ± 0.02 0.06 ± 0.01 A
 B-MLV 1.09 ± 0.05 1.13 ± 0.02 1.08 ± 0.08 1.12 ± 0.10 1.11 ± 0.04 D
 NB-MLV 1.13 ± 0.07 1.09 ± 0.09 1.08 ± 0.11 1.09 ± 0.05 1.12 ± 0.08 D
Fv1nn_
 N-MLV 1.17 ± 0.04 1.15 ± 0.04 1.09 ± 0.07 1.18 ± 0.05 1.10 ± 0.06 D
 B-MLV 1.12 ± 0.11 1.11 ± 0.04 1.07 ± 0.02 0.37 ± 0.05 0.09 ± 0.02 B
 NB-MLV 1.12 ± 0.10 1.11 ± 0.05 1.12 ± 0.13 1.05 ± 0.06 1.11 ± 0.05 D
Fv1bb_
 N-MLV 1.07 ± 0.17 1.04 ± 0.05 1.07 ± 0.04 0.15 ± 0.04 0.06 ± 0.02 B
 B-MLV 1.14 ± 0.04 1.15 ± 0.05 1.09 ± 0.11 0.77 ± 0.04 0.22 ± 0.01 C
 NB-MLV 1.13 ± 0.03 1.04 ± 0.06 1.07 ± 0.10 0.20 ± 0.01 0.05 ± 0.02 B
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To test for possible effects on protein stability of per-
muting the different Fv1 alleles we compared the protein 
levels of the different Fv1 chimeras (Fig.  4). No single 
change explained the difference in expression levels of the 
different alleles of Fv1. All chimeras have a protein level 
between that of Fv1n and Fv1b with the sole exception of 
Fv1nbn that has a higher protein level than Fv1n. Only 
in one case out of five in which “high induction” condi-
tions are required for full restriction protein concentra-
tion (nn_ compared to Fv1n) can a reduction in protein 
concentration explain the need for higher expression. In 
the remaining cases, e.g. bb_ compared to Fv1b, protein 
expression is at least as high in the new construct as in 
the parental allele (Fig.  4) while more Fv1 as judged by 
induction conditions is required for restriction (Table 2).
Retroviral restriction activities of wild mice Fv1 at different 
expression levels
We have previously reported restriction activities against 
EIAV and FFV of Fv1 alleles from wild mice, identified 
using the non-inducible vector LxIY-Fv1 (EYFP version 
of LxIG-Fv1, Fig. 1a) in our two colour restriction assay 
[8]. Although these novel restriction activities appeared 
to be equally strong as those against MLV under condi-
tions of overexpression, it is possible that they repre-
sent consequences of overexpression. For Fv1 from wild 
mice, the natural expression levels are not known due to 
the lack of cell lines derived from these mice. We there-
fore compared the retroviral restriction activities and 
expression levels of selected Fv1 alleles (Fv1b, Fv1MIN2, 
Fv1SPR1, Fv1MAC and Fv1CAR1) at different induction 
levels using the pTYIx-Fv1 vector, to gauge the strength 
of these restriction activities. Fv1MIN2 from M. minuto-
ides was selected because while some studies suggested 
that this Fv1 allele restricts N-MLV and B-MLV but 
not NB-MLV [15, 54], our previous restriction analy-
sis suggested that it also restricts NB-MLV [8]. Fv1SPR1 
(from M. spretus), Fv1MAC (from M. macedonicus) and 
Fv1CAR1 (from M. caroli) were chosen on the basis of 
restriction activities against non-gammaretroviruses [8].
We used the TYIx-Fv1 vector together with the non-
inducible LxIY-Fv1 vector to allow the expression of 
Fv1 at a wide range of concentrations ranging from sub-
endogenous to overexpression, for analysis of restric-
tion activities against MLV, EIAV and FFV after treating 
cells with different amount of doxycycline (Table  3). At 
10 ng/mL doxycycline, the restriction phenotype of Fv1b 
appears to be closest to that of endogenous Fv1b, with 
full restriction of N-MLV and minimal inhibition of NB-
MLV. At this induction level, some restriction activi-
ties that appeared strong when Fv1 was overexpressed 
become significantly weaker (e.g. NB-MLV inhibition 
by Fv1b and Fv1MIN2), while other activities remain 
strong at this induction level (e.g. N-MLV restriction by 
Fv1b and Fv1MIN2). These restriction data from multi-
ple expression levels allowed us to compare the strength 
of restriction activities of the same Fv1 against differ-
ent retroviruses. Consistent with earlier data (Table  1), 
the restriction activity of Fv1b appeared to be strongest 
against N-MLV, moderate against NB-MLV, and weakest 
against B-MLV. In contrast, Fv1MIN2 appears to restrict 
both N-MLV and B-MLV strongly, and show weaker 
restriction against NB-MLV. Fv1SPR1 had similar restric-
tion activities against N-MLV, B-MLV and EIAV even at 
low expression levels. Fv1MAC showed stronger restric-
tion activity against EIAV than against N-MLV.
Since the expression level of different Fv1s can be 
rather different at the same induction level (Fig.  2), we 
analysed the Fv1 protein levels in all five sets of condi-
tions (Fig. 5a, b; Additional file 5). Indeed, there are large 
differences in the protein levels of different Fv1s at the 
same concentration of added doxycycline. The five Fv1s 
could be divided into two groups based on their expres-
sion levels. When expressed from the pLxIY vector, aver-
age protein levels of Fv1MIN2, Fv1MAC and Fv1CAR1 
were ninefold higher than that of Fv1b and Fv1SPR1 
(Fig.  5b). This was even higher than seen with Fv1n, 
which was fourfold higher than Fv1b (Fig. 2). To compare 
the restriction activities of different Fv1s against the same 
virus, we plotted the Fv1 restriction activities against the 
Fv1 protein levels (Fig.  5c–g). At all Fv1 protein levels, 
the restriction of N-MLV by Fv1b, Fv1MIN2 and Fv1SPR1 
was similar but much stronger than that of Fv1MAC. The 
quantity of Fv1 required to fully restrict N-MLV (restric-
tion ratio of ≤0.3) was approximately 30-fold higher 
for Fv1MAC than that required for Fv1b, Fv1MIN2 
and Fv1SPR1 (Fig.  5c). Among the non-MLV restric-
tion activities the restriction of EIAV by Fv1SPR1 was 
also stronger than that of Fv1MAC, with about 20-fold 
more Fv1MAC required for full restriction of EIAV 
compared to Fv1SPR1 (Fig. 5f ). Additionally, the restric-
tion of EIAV by Fv1MAC and the restriction of FFV by 
Fv1CAR1 appeared to be weaker and similar to the NB-
MLV restriction activity by Fv1b (Fig. 5e–g). In contrast, 
Fv1SPR1 exhibited strong EIAV restriction activity when 
expressed at levels comparable to those required for full 
restriction of N-MLV restriction by Fv1b, Fv1MIN2 and 
Fv1SPR1. In this case at least the novel restriction activity 
does not require overexpression.
Discussion
We have developed new retroviral delivery vectors that 
allow the inducible expression of restriction factors, 
while simultaneously allowing use of the two colour 
FACS assay so that reduction in infectivity of tester virus 
can be compared to that of an internal control. Using 
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these vectors, we examined the relationship between 
Fv1 overexpression and the gain of additional restriction 
activities. Our studies provided definitive evidence that 
NB-MLV restriction and partial restriction of B-MLV 
could be achieved by overexpressing Fv1b, whereas over-
expression of Fv1n does not lead to inhibition of N-MLV 
and NB-MLV. We suggest that the difference in the ability 
to gain additional restriction activities could be explained 
the differences in relative binding affinities towards dif-
ferent MLVs. In our previous binding study, we showed 
specific binding of Fv1n to polymerised CA of B-MLV, 
but not N-MLV or NB-MLV [1]. In contrast, we saw 
essentially no difference in binding of Fv1b to polymer-
ised CA of N-MLV, B-MLV and NB-MLV [1]. Subse-
quent binding studies at different concentration of Fv1b 
all showed similar binding of Fv1b to CA from all MLVs 
(Wilson Li, PhD thesis University College London). These 
data would indicate that whereas Fv1n has much stronger 
affinity for CA of B-MLV compared to CA of N-MLV and 
NB-MLV, the differences with Fv1b are much smaller. As 
a result, the slightly weaker affinities of Fv1b for NB-MLV 
and B-MLV can be overcome by overexpression but simi-
lar levels of overexpression would not be sufficient for 
detectable inhibition of N-MLV and NB-MLV by Fv1n. 
Differential binding of Fv1b to CA of different MLVs may 
only be observable at very low Fv1 concentrations, where 
the amount of bound Fv1b would be below the detection 
limit of the binding assay.
At induction levels of Fv1b where full restriction of 
N-MLV was observed, NB-MLV was inhibited by at 
least 20 % (Tables 1, 2). This would suggest that even at 
endogenous levels, Fv1b would weakly inhibit NB-MLV. 
Previous data from B-3T3 cells overexpressing Fv1n are 
consistent with this idea [5]. In that study it was shown 
that overexpression of one Fv1 allele in cells with endog-
enous expression of another Fv1 allele resulted in the 
restriction phenotype of the overexpressed Fv1, and abo-
lition of the endogenous phenotype [5]. In experiments 
in which B-3T3 cells were transduced with the deliv-
ery vector LxIG-Fv1n, cells expressing exogenous Fv1n 
showed a 20 % increase in the number of NB-tropic MLV 
compared to non-transduced controls [5], suggesting a 
level of inhibition by exogenously expressed Fv1b similar 
to that observed at low induction levels using the induc-
ible vectors.
The protein expression levels of Fv1 vary from allele 
to allele (Figs. 2, 4). Thus, Fv1n, Fv1MAC, Fv1CAR1 and 
Fv1MIN2 are present at much higher levels than Fv1b and 
Fv1SPR1 (Fig. 5). The difference between Fv1n and Fv1b 
is independent of transcription level (Fig.  4) suggesting 
differential protein stability. This cannot be explained in 
terms of the individual amino acid differences between 
Fig. 4 Comparison of endogenous and overexpression levels of Fv1n and Fv1b. a Quantitative western blot analysis of Fv1 in N-3T3, B-3T3 and 
MDTF transduced with LxIG-Fv1 deliver vectors containing wild type or mutant Fv1 ORF. Fv1 was detected using an anti-Fv1 antibody and the LI-
COR Odyssey infrared fluorescent western blot system. Quantities of Fv1 in lysate samples were interpolated from a standard curve generated using 
fluorescent signals from known quantities of purified Fv1NTD protein loaded on the same gel. Numbers under the blot indicate the quantities of Fv1 
in each sample relative to that in the N-3T3 sample. b A bar chart showing the mean and mean deviation values from two independent quantita-
tion experiments
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the two proteins (Fig.  4). Although sequences at posi-
tions 358, 399 and the C-terminus could affect the over-
expression levels of Fv1n and Fv1b (Fig.  4), individual 
residues at these positions could not explain the over-
expression level of wild mice Fv1s. For example, both 
Fv1MAC and Fv1SPR1 have the Fv1n residues K358 and 
V399, and Fv1b-like long C-termini [8], but the expres-
sion levels of Fv1MAC were much higher than those of 
Fv1SPR1 (Fig.  5). It is conceivable that the rabbit poly-
clonal anti-Fv1 used in quantitative western blots, which 
was raised against a purified fragment corresponding to 
amino acids 20–200 of Fv1NTD, binds more strongly to 
Fv1MAC than to Fv1SPR1 due to sequence variation in 
the Fv1NTD. However, this seems highly unlikely since 
Fv1MAC only differs from Fv1SPR1 at two amino acids 
within amino acids 20–200 [8].
The relationship between Fv1 concentration and 
restriction is complex. In some cases, typified by Fv1n, 
restriction properties are unaffected by concentration. 
Thus, it seems clear that at least some of the novel activi-
ties we observed in wild mice [8], e.g. Fv1MAC restric-
tion of EIAV, do not require overexpression. In others, 
such as NB-MLV restriction by Fv1b, restriction only 
becomes clearly evident following overexpression. Such 
a relationship may explain the differences in restriction 
specificities of Fv1MIN2 reported previously [8, 15, 54]. 
Table 3 Restriction activity of selected Fv1 alleles against different retroviruses at different Fv1 expression levels
We arbitrarily divide restriction activity into three levels; Full, shown in bolditalic (restriction ratio ≤0.3), Partial, indicated in italics (0.3 < ratio ≤ 0.7) and None 
(ratio > 0.7)
Table shows the results from this study using the TYIx-Fv1 inducible vector, with mean and standard deviation values calculated from two independent duplicate 
experiments. The last column shows results from our previous study using the non-inducible LxIY-Fv1 vector in MDTF cells [8]. n.d., not determined
Vector TYIx-Fv1 LxIY-Fv1
Dox (ng/mL) 0 10 100 1000 0
Fv1b
 N-MLV 0.46 ± 0.02 0.21 ± 0.01 0.14 ± 0.02 0.13 ± 0.02 0.09 ± 0.01
 B-MLV 1.09 ± 0.05 0.96 ± 0.05 0.83 ± 0.05 0.77 ± 0.03 0.48 ± 0.02
 NB-MLV 0.93 ± 0.06 0.51 ± 0.03 0.35 ± 0.01 0.33 ± 0.04 0.16 ± 0.01
 EIAV n.d. n.d. n.d. n.d. 0.52 ± 0.01
 FFV n.d. n.d. n.d. n.d. 1.00 ± 0.02
Fv1MIN2
 N-MLV 0.43 ± 0.02 0.18 ± 0.02 0.14 ± 0.02 0.11 ± 0.02 0.04 ± 0.01
 B-MLV 0.33 ± 0.01 0.16 ± 0.03 0.12 ± 0.01 0.11 ± 0.02 0.04 ± 0.01
 NB-MLV 1.02 ± 0.04 0.52 ± 0.02 0.27 ± 0.03 0.23 ± 0.05 0.10 ± 0.01
 EIAV n.d. n.d. n.d. n.d. 1.08 ± 0.04
 FFV n.d. n.d. n.d. n.d. 1.00 ± 0.02
Fv1SPR1
 N-MLV 0.70 ± 0.04 0.28 ± 0.01 0.17 ± 0.02 0.16 ± 0.02 0.12 ± 0.01
 B-MLV 0.75 ± 0.04 0.31 ± 0.05 0.19 ± 0.01 0.19 ± 0.02 0.13 ± 0.01
 NB-MLV n.d. n.d. n.d. n.d. 1.17 ± 0.01
 EIAV 0.65 ± 0.06 0.32 ± 0.03 0.24 ± 0.02 0.24 ± 0.02 0.20 ± 0.01
 FFV n.d. n.d. n.d. n.d. 1.02 ± 0.01
Fv1MAC
 N-MLV 1.10 ± 0.04 0.70 ± 0.02 0.35 ± 0.02 0.30 ± 0.02 0.18 ± 0.01
 B-MLV 1.08 ± 0.09 1.08 ± 0.02 1.10 ± 0.06 1.02 ± 0.02 1.24 ± 0.02
 NB-MLV n.d. n.d. n.d. n.d. 1.24 ± 0.01
 EIAV 0.79 ± 0.02 0.44 ± 0.02 0.27 ± 0.02 0.26 ± 0.03 0.21 ± 0.01
 FFV n.d. n.d. n.d. n.d. 1.01 ± 0.03
Fv1CAR1
 N-MLV n.d. n.d. n.d. n.d. 1.21 ± 0.07
 B-MLV n.d. n.d. n.d. n.d. 1.15 ± 0.03
 NB-MLV n.d. n.d. n.d. n.d. 1.17 ± 0.01
 EIAV n.d. n.d. n.d. n.d. 1.17 ± 0.09
 FFV 0.95 ± 0.01 0.40 ± 0.04 0.18 ± 0.02 0.18 ± 0.03 0.13 ± 0.01
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In these studies, restriction of N-MLV, B-MLV but not 
NB-MLV were observed in cells derived from M. n. minu-
toides, as well as in MDTF cells transduced with the ret-
roviral delivery vector LCNX2 with Fv1MIN2 expression 
driven by a CMV promoter [15, 54]. In contrast, studies 
in transduced MDTF cells using the LxIY-Fv1 vector and 
the two colour FACS assay, also showed restriction of 
NB-MLV [8]. Here we showed that at lower expression 
levels, Fv1MIN2 has stronger restriction activities against 
N-MLV and B-MLV than against NB-MLV (Table  2). 
Fig. 5 Restriction activity and expression levels of selected Fv1 alleles. a Quantitative western blot analysis of various Fv1 alleles in MDTF-R18 cells 
transduced with either TYIx-Fv1 or LxIY-Fv1 vectors. Fv1 was detected using an anti-Fv1 antibody and the LI-COR Odyssey infrared fluorescent west-
ern blot system. Transduced cells were treated with 0, 10, 100, or 1000 ng/mL doxycycline for 24 h before challenging with EGFP-expressing tester 
viruses. Quantities of Fv1 in lysate samples were interpolated from a standard curve generated using fluorescent signals from known quantities of 
purified Fv1NTD protein loaded on the same gel. Numbers under the blot indicate the quantities of Fv1 in each sample relative to that in the LxIY-
Fv1b sample. b Graph showing the mean and standard deviation values of relative quantities of selected Fv1 alleles in MDTF-R18 cells transduced 
with TYIx-Fv1 or LxIY-Fv1 vector relative to that in the LxIY-Fv1b sample. Two repeated quantitative western blots were carried for each of two 
samples of transduced cells, and the results are also listed in Table S2. Cells transduced with TYIx-Fv1 vectors were treated with 0 (black), 10 (red), 100 
(blue) or 1000 (green) ng/mL dox for 24 h. Cells transduced with LxIY-Fv1 vectors (purple) were not treated with dox. c–g Scatter plots showing mean 
values and standard deviation of c N-MLV, d B-MLV, e NB-MLV, f EIAV and g FFV restriction activities from Table 2 against mean relative Fv1 protein 
levels from Fig. 3b. Blue squares, Fv1b; red upright triangles, Fv1MIN2; green inverted triangles, Fv1SPR1; purple diamonds, Fv1MAC; orange circles, 
Fv1CAR1. The two dotted horizontal lines indicate the boundaries between full restriction and partial restriction (0.7), and between partial restriction 
and no restriction (0.3)
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Therefore, it is possible that the LxIY-Fv1 vector 
expresses Fv1MIN2 at a higher level than from LCNX2, 
thereby allowing the restriction of NB-MLV.
If restriction activities are only fully manifest at overex-
pression levels, with only partial restriction at induction 
levels close to that of endogenous Fv1b, it seems reason-
able to question of the biological significance of such par-
tial restriction activities. Although Fv1 does not appear 
to be interferon inducible (Vicky Felton, PhD thesis Uni-
versity College London), it is possible that the endog-
enous levels of some wild mice Fv1s are much higher, 
therefore allowing full restriction. Since the endogenous 
level of Fv1n in N-3T3 cells is threefold higher than that 
of Fv1b in B-3T3 cells (Fig. 2), in some mice the endog-
enous level may be sufficiently high for full restriction to 
occur. If overexpression of Fv1 allows the gain of restric-
tion activities, Fv1 may be under evolutionary pressure 
not only to alter its binding properties to allow recogni-
tion of CA from circulating viruses, but also to increase 
its expression levels, either at the transcriptional level or 
by enhanced protein stability. It would be interesting to 
study the any such variation among wild mice, and to ask 
whether there are adaptations designed to increase the 
endogenous Fv1 levels, and if so whether there are lim-
its to the expression levels of wild mice Fv1. Alternatively 
it may be that the combined inhibition exerted by the 
partial restriction of Fv1 and by other restriction factors 
such as murine APOBEC3 is sufficient to confer protec-
tion against the target virus [55]. To begin to investigate 
questions associated with Fv1 expression in vivo, we have 
initiated studies of Fv1 expression in fresh tissues. An ini-
tial experiment reveals that expression levels in thymo-
cytes are comparable to that seen in fibroblast lines and 
rather higher than in splenocytes (Additional file 6).
The biological significance of these partial restriction 
activities remains open to question. Some of these par-
tial restriction activities might represent a response to a 
novel threat. As Fv1 evolves to recognise a new emerg-
ing virus, it accumulates mutations that lead to the 
decrease in restriction activity against its old target. It 
is also possible that some of these Fv1 alleles are under 
selection from multiple retroviruses simultaneously, and 
Fv1 has been selected to inhibit all of these viruses, at the 
cost of weaker restriction against each of these viruses. 
It has been shown that forced passage of B-MLV in cells 
expressing Fv1n rapidly leads to the isolation of NB-MLV, 
while forced passage of N-MLV in Fv1b cells does not 
[30, 56]. The partial restriction activity against NB-MLV 
by Fv1b could have an important role in preventing the 
emergence of NB-tropic virus resulting from adaptation 
of B-MLV.
Conclusions
Fv1 can restrict retrovirus replication even when 
expressed at very low levels, with different alleles show-
ing different restriction specificities. An inducible expres-
sion system was established to probe the consequences 
of factor overexpression. Although novel specificities 
were revealed with several alleles, in most cases restric-
tion specificity remained unchanged upon overexpres-
sion. It thus appears that the activities of Fv1 directed 
against non-MLVs are manifested at levels equivalent to 
those that protect inbred mice against MLV. In turn this 
implies that they have been selected to confer protection 
against undefined novel viruses.
Methods
Plasmids and DNA primers
The pLxIG-Fv1 (formerly designated LFv1IEG) vectors 
for non-inducible expression of EGFP and wild-type, 
“mix-and-match” mutant or C-terminal tail deletion 
mutant of Fv1n and Fv1b have been described previ-
ously [5, 6]. The Gateway destination vector pLxIY-DEST 
(formerly designated pLgatewayIRESEYFP) for non-
inducible expression of EYFP and restriction factor has 
been described previously [57]. The Gateway entry vec-
tors pENTR-Fv1 and delivery vectors LxIY-Fv1 with 
Fv1n, Fv1b, Fv1MAC, Fv1MIN2, Fv1SPR1, and Fv1CAR1 
ORFs have been previously described [8]. The self-inac-
tivating retroviral vector QCXIX was obtained from 
ClonTech. pLenti-CMV-rtTA3-Blast (Addgene #26429), 
pLenti-CMVTRE3G-Puro-DEST (Addgene #27565), and 
pENTR-LUC (Addgene #17473) were constructed by 
Eric Campeau [58]. The DNA primers (Sigma) used for 
PCR and site-directed mutagenesis reactions are listed in 
Additional file 7.
Construction of inducible Gateway destination vectors
The inducible Gateway (Life Technologies) destination 
vectors pTGx-DEST, pTGIx-DEST, pTYx-DEST, pTYIx-
DEST were constructed using pQCXIX (ClonTech) as 
the backbone plasmid. pQCXIX contains the CMV pro-
moter, the 5′ MCS, the EMCV IRES sequence and the 3′ 
MCS. The TRE3G promoter was amplified by PCR from 
pLenti-CMVTRE3G-Puro-DEST (Addgene #27565) 
with the primers TRE3G-F and TRE3G-R, and inserted 
between ClaI and NotI sites of pQCXIX to replace the 
CMV promoter. The EGFP sequence was amplified from 
pLxIG-Fv1n with the primers EGFP-F and EGFP-R, while 
the EYFP sequence was amplified from pLxIY-DEST 
using the same primers, both were inserted between NotI 
and EcoRI sites of the 5′ MCS of pQCXIX. To construct 
pTGIx-DEST and pTYIx-DEST, the blunt Gateway DEST 
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cassette was obtained by digesting pLenti-CMVTRE3G-
Puro-DEST with EcoRV, and inserted into the EcoRV site 
in the 3′MCS of pQCXIX. To construct pTGx-DEST and 
pTYx-DEST, the DEST cassette was inserted between the 
EcoRI site in 5′MCS and the EcoRV site in the 3′MCS of 
pQCXIX.
Cloning of inducible delivery vectors
Sequences for Fv1n, Fv1b and “mix and match” mutants 
were amplified from pLxIG-Fv1 vectors by PCR using 
the forward primer TOPO-Fv1-F which introduces the 5′ 
CACC sequence, and one of the reverse primers: TOPO-
Fv1n-R for Fv1bbn, Fv1bnn and Fv1nbn; TOPO-Fv1b-R 
for Fv1nnb, Fv1nbn and Fv1bnb; and TOPO-Fv1-notail-
R for Fv1nn_ and Fv1bb_. PCR products with Fv1 ORFs 
were inserted into the pENTR-D-TOPO vector (Life 
Technologies) by TOPO reaction, in order to obtain 
pENTR-Fv1 entry vectors. Entry vectors for Fv1n and 
Fv1b mutants were used in LR reactions with LR clon-
ase (Life Technologies) to insert the Fv1 ORF into either 
pTGx-DEST or pTGIx-DEST vectors. Similarly, Fv1b and 
wild mice Fv1 ORFs in entry vectors were inserted into 
either pTYx-DEST or pTYIx-DEST vectors. To obtain the 
mutant delivery vector pTGx-Fv1b-AGG, the Fv1b ORF 
with mutated start codon was amplified by PCR using 
the primers TOPO-AGG-Fv1-F and TOPO-Fv1b-R, 
inserted into pENTR-D-TOPO by TOPO reaction, and 
finally inserted to pTGx-DEST by LR reaction. pLenti-
CMVTRE3G-Puro-LUC was generated by inserting the 
Firefly Luciferase ORF from pENTR-LUC into pLenti-
CMVTRE3G-Puro-DEST by LR reaction.
Site directed mutagenesis
To introduce the TAATAA double stop codon into 
EGFP ORF of pTGx-Fv1b, a point mutation was gen-
erated by site directed mutagenesis using the prim-
ers TGx-TAATAA-F and TGx-TAATAA-R. Mutation 
of the Fv1 start codon of pLxIG-Fv1n was carried out 
by site directed mutagenesis using the primers pLxIG-
Fv1n-AGG-F and pLxIG-Fv1n-AGG-R. Each 50  μL 
QuikChange site directed mutagenesis PCR reaction 
contained 50 ng of plasmid template, 10 pmol of forward 
primer, 10 pmol of reverse primer, 200 μM of each dNTP, 
2.5 U of PfuUltra high fidelity polymerase (Agilent Tech-
nologies) in the supplied buffer. PCR reaction was per-
formed at 95 °C for 5 min; followed by 12 cycles of 95 °C 
for 1 min, 55  °C for 1.5 min, and 68  °C for 15 min; and 
finally 68  °C for 15. Template DNAs were digested with 
30 U of DpnI (Roche) at 37 °C for 2 h, and the amplified 
mutant plasmids were concentrated by ethanol precipita-
tion before transforming XL10 Gold ultracompetent cells 
(Agilent Technologies). The introduction of mutations 
was verified by sequencing [2].
Cells and virus production
N-3T3, B-3T3, MDTF, MDTF-R18, and 293T cells were 
maintained in DMEM containing 10 % foetal calf serum 
and 1 % penicillin and streptomycin. Preparation of ret-
roviral or lentiviral vectors were carried by transient 
transfection of 293T with 3 plasmids providing Env, 
Gag-Pol and genome functions, as previously described 
[5, 57]. Delivery retroviral vectors were prepared by co-
transfecting pcz-VSVG, pHIT60, and a retroviral vector 
for expression of Fv1 and either EGFP or EYFP. Delivery 
lentiviral vectors were prepared by co-transfecting pcz-
VSVG, p8.91, and a lentiviral vector with either blasti-
cidin or puromycin resistance gene. MLV tester viruses 
were generated by co-transfection of pcz-VSV-G, either 
pczCFG2fEGFPf for EGFP tester or pczCFG2fEYFPf 
for EYFP tester, and either pCIGN for N-MLV, pCIGB 
for B-MLV, or pHIT60 for NB-MLV [5, 57]. EIAV tester 
viruses were made by co-transfection of pczVSV-G, 
pONY3.1 and pONY8.4ZCG or pONY4.1Z [59], while 
FFV tester viruses were produced with pciSFV-1envwt 
and pcDWF003 [60]. MLV was frozen in aliquots at 
−80  °C, while EIAV and FFV were freshly prepared for 
each experiment.
Generation and screening of MDTF cells expressing rtTA3
MDTF cells were transduced at a MOI less than 0.1 with 
a lentiviral vector made using the pLenti-CMV-rtTA3-
Blast plasmid, for the expression of rtTA3 and the blasti-
cidin resistance gene. Transduced cells were selected with 
10 μg/mL blasticidin (Sigma), and single-cell clones were 
picked from the selected population. To test the leaki-
ness and induction of the PTRE3G promoter in these cells, 
each clone was transduced at a MOI <0.1 with a lentivi-
ral delivery vector made using the pLenti-CMVTRE3G-
Puro-LUC vector, which allows the expression of the 
firefly luciferase gene under the PTRE3G promoter, and the 
expression of puromycin resistance gene under a sepa-
rate promoter. After selection with 10 µg/mL puromycin, 
cells were treated with or without 1  μg/mL doxycycline 
for 24  h. Cells were lysed with the supplied lysis buffer 
before analysis of luciferase activity using the Luciferase 
Assay System (Promega) and the Synergy 2 plate reader 
(Biotek). Relative luminescence signal was normalised 
to the cell count to obtain normalised relative luciferase 
activity. Luciferase activity was normalised against cell 
count from duplicated wells. The MDTF-R18 clone was 
selected for its low leakiness and high induction, and was 
used for restriction analyses in this study.
Restriction assays
The procedure for studying restriction activity was modi-
fied from the transient two colour FACS assay previ-
ously developed for non-inducible vectors [5, 57]. Briefly, 
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MDTF-R18 cells were transduced with one of the retro-
viral delivery vectors for the expression of Fv1 and either 
EGFP or EYFP. 72 h post-transduction, transduced cells 
were reseeded and incubated with up to 1000 ng/mL dox-
ycycline in DMEM for 24 h, before infection with tester 
viruses. 10  µg/mL doxycycline was added to each well 
at 24 h post-infection, and cells were subjected to FACS 
analysis using FACSVerse, LSR II or LSRFortessa X-20 
(BD) flow cytometers at 72 h post-infection. The percent-
age of tester-positive cells in the Fv1-positive population 
and in the Fv1-negative population were determined and 
compared using the FlowJo analysis software, in order to 
calculate the restriction ratios. Ratios of <0.3 were taken 
as full restriction; ratios between 0.3 and 0.7 were taken 
to represent partial restriction; while ratios greater 0.7 
were taken to represent no restriction. For restriction 
assays in cells with superexpression of Fv1, MDTF-R18 
cells were transduced with different volume of retroviral 
delivery viruses or control viruses expressing EGFP. At 
72 h post-transduction, transduced cells were mixed with 
equal number of untransduced cells and reseeded for 
infection with EYFP tester viruses on the next day. FACS 
analyses were carried out at 72 h post-infection.
Quantitative western blots
MDTF-R18 cells transduced with retroviral delivery 
vectors were incubated with up to 1000 ng/mL doxycy-
cline for 24 h, before cells were harvested and frozen at 
−80  °C as cell pellets. Frozen N-3T3, B-3T3, and trans-
duced MDTF-R18 cells were lysed in 100 µL RIPA buffer 
(Thermo Fisher) supplemented with complete EDTA-free 
protease inhibitors (Roche) at 4  °C for 30  min, clarified 
by centrifugation at 4  °C for 10  min, before determina-
tion of total protein concentrations by BCA protein assay 
(Thermo Fisher). Lysate samples were boiled in loading 
buffer containing 2 % SDS and 2.5 % β-mercaptoethanol. 
Typically 25  µg of lysate was loaded into each well of a 
1.5 mm 10 % polyacrylamide gel, along with 5 µL per well 
of known quantity of recombinant Fv1NTD (20–200) 
protein [36]. After SDS-PAGE, proteins were transferred 
to Immobilon-FL PVDF membrane (Merck Millipore) 
using the Trans-Blot SD semi-dry transfer cell (Bio-rad). 
Membranes were blocked with 5  % non-fat dry milk in 
PBS (PBS-milk) at 4 °C overnight. Fv1 was detected using 
a rabbit polyclonal primary antibody (in house #6689) 
raised against purified fragment of the Fv1NTD (20–200) 
[36]. The primary antibody was diluted 1 in 1000 in PBS-
milk, and incubated with the membrane for 1 h at room 
temperature, before washing 4 times with PBS containing 
0.1 % Tween-20 (PBS-T). The membrane was then incu-
bated with the IRDye800CW-conjugated goat polyclonal 
secondary antibody diluted 1 in 5000 in PBS-milk sup-
plemented with 0.01 % SDS for 1 h at room temperature, 
before washing 4 times with PBS-T. After a final wash 
with PBS, the membrane was scanned using the Odyssey 
infrared fluorescent imaging system (LI-COR). Fluores-
cent intensity of Fv1 and Fv1NTD bands were measured 
using the ImageStudio software (LI-COR). The quantity 
of Fv1 in each sample was determined by interpolation of 
the measured signal of each Fv1 band to a standard curve 
generated using fluorescent signals from known amount 
of Fv1NTD on the same blot. In samples of transduced 
MDTF-R18 cells, only a fraction of cells were transduced 
with the retroviral delivery virus. Therefore, the amount 
of Fv1 in the transduced population was calculated by 
dividing the total quantity of Fv1 in each sample by the 
proportion of Fv1-positive cells.
Authors’ contributions
WL, MWY and VF performed the experiments described. WL and JPS con-
ceived the study. WL and JPS wrote the manuscript. All authors read and 
approved the final manuscript.
Author details
1 Retrovirus–Host Interactions Laboratory, The Francis Crick Institute, Mill Hill 
Laboratory, The Ridgeway, Mill Hill, London NW7 1AA, UK. 2 Faculty of Medi-
cine, Imperial College London, London SW7 2AZ, UK. 
Acknowledgements
We are grateful to Ian Taylor for insightful comments on the manuscript.
Competing interests
The authors declare that they have no competing interests.
Funding
The United Kingdom Medical Research Council supported this study through 
core grants to the National Institute for Medical Research and the Francis 
Crick Institute. The Medical Research Council played no role in the design of 
the study and collection, analysis, and interpretation of data or in writing the 
manuscript.
Received: 4 March 2016   Accepted: 16 June 2016
Additional files
Additional file 1. Screening of MDTF single cell clones expressing rtTA3.
Additional file 2. Determination of the concentration of doxycycline 
required foroptimal GFP separation.
Additional file 3. Timing for the addition of the final high dose of 
doxycycline.
Additional file 4. Data from quantitative western blot analysis of Fv1n 
and Fv1b expression levels in N-3T3, B-3T3 and transduced MDTF-R18 
cells.
Additional file 5. Data from quantitative western blot analysis of Fv1 
expression levels in transduced MDTF-R18 cells.
Additional file 6. Expression of Fv1 in fresh tissues.
Additional file 7. Primers used in this study.
Page 16 of 17Li et al. Retrovirology  (2016) 13:42 
References
 1. Hilditch L, Matadeen R, Goldstone DC, Rosenthal PB, Taylor IA, Stoye 
JP. Ordered assembly of murine leukemia virus capsid protein on lipid 
nanotubes directs specific binding by the restriction factor, Fv1. Proc Natl 
Acad Sci USA. 2011;108:5771–6. doi:10.1073/pnas.1100118108.
 2. Stremlau M, Perron M, Lee M, Li Y, Song B, Javanbakht H, et al. Specific 
recognition and accelerated uncoating of retroviral capsids by the TRI-
M5alpha restriction factor. Proc Natl Acad Sci USA. 2006;103(14):5514–9. 
doi:10.1073/pnas.0509996103.
 3. Fricke T, White TE, Schulte B, de Souza Aranha Vieira DA, Dharan A, 
Campbell EM, et al. MxB binds to the HIV-1 core and prevents the 
uncoating process of HIV-1. Retrovirology. 2014;11(1):68. doi:10.1186/
PREACCEPT-6453674081373986.
 4. Nisole S, Lynch C, Stoye JP, Yap MW. A Trim5-cyclophilin A fusion protein 
found in owl monkey kidney cells can restrict HIV-1. Proc Natl Acad Sci 
USA. 2004;101:13324–8. doi:10.1073/pnas.0404640101.
 5. Bock M, Bishop KN, Towers G, Stoye JP. Use of a transient assay for study-
ing the genetic determinants of Fv1 restriction. J Virol. 2000;74:7422–30.
 6. Bishop KN, Bock M, Towers G, Stoye JP. Identification of the regions of Fv1 
necessary for murine leukemia virus restriction. J Virol. 2001;75:5182–8. 
doi:10.1128/JVI.75.11.5182-5188.2001.
 7. Stevens A, Bock M, Ellis S, Le Tissier P, Bishop KN, Yap MW, et al. Retroviral 
capsid determinants of Fv1 NB and NR tropism. J Virol. 2004;78:9592–8. 
doi:10.1128/JVI.78.18.9592-9598.2004.
 8. Yap MW, Colbeck E, Ellis SA, Stoye JP. Evolution of the retroviral 
restriction gene Fv1: inhibition of non-MLV retroviruses. PLoS Pathog. 
2014;10(3):e1003968. doi:10.1371/journal.ppat.1003968.
 9. Goujon C, Moncorge O, Bauby H, Doyle T, Barclay WS, Malim MH. Transfer 
of the amino-terminal nuclear envelope targeting domain of human MX2 
converts MX1 into an HIV-1 resistance factor. J Virol. 2014. doi:10.1128/
JVI.01269-14.
 10. Busnadiego I, Kane M, Rihn SJ, Preugschas HF, Hughes J, Blanco-Melo 
D, et al. Host and viral determinants of Mx2 antiretroviral activity. J Virol. 
2014. doi:10.1128/JVI.00214-14.
 11. Song B, Gold B, O’Huigin C, Javanbakht H, Li X, Stremlau M, et al. The 
B30.2(SPRY) domain of the retroviral restriction factor TRIM5alpha exhib-
its lineage-specific length and sequence variation in primates. J Virol. 
2005;79:6111–21. doi:10.1128/JVI.79.10.6111-6121.2005.
 12. Ohkura S, Yap MW, Sheldon T, Stoye JP. All three variable regions of the 
TRIM5alpha B30.2 domain can contribute to the specificity of retrovirus 
restriction. J Virol. 2006;80:8554–65. doi:10.1128/JVI.00688-06.
 13. Nakayama EE, Miyoshi H, Nagai Y, Shioda T. A specific region of 37 amino 
acid residues in the SPRY (B30.2) domain of African green monkey 
TRIM5alpha determines species-specific restriction of simian immuno-
deficiency virus SIVmac infection. J Virol. 2005;79:8870–7. doi:10.1128/
JVI.79.14.8870-8877.2005.
 14. Stremlau M, Perron M, Welikala S, Sodroski J. Species-specific variation 
in the B30.2(SPRY) domain of TRIM5alpha determines the potency of 
human immunodeficiency virus restriction. J Virol. 2005;79:3139–45. 
doi:10.1128/JVI.79.5.3139-3145.2005.
 15. Yan Y, Buckler-White A, Wollenberg K, Kozak CA. Origin, antiviral function 
and evidence for positive selection of the gammaretrovirus restriction 
gene Fv1 in the genus Mus. Proc Natl Acad Sci USA. 2009;106:3259–63. 
doi:10.1073/pnas.0900181106.
 16. Sironi M, Biasin M, Cagliani R, Gnudi F, Saulle I, Ibba S, et al. Evolutionary 
analysis identifies an MX2 haplotype associated with natural resistance to 
HIV-1 infection. Mol Biol Evol. 2014;31(9):2402–14. doi:10.1093/molbev/
msu193.
 17. Sawyer SL, Wu LI, Emerman M, Malik HS. Positive selection of primate TRI-
M5alpha identifies a critical species-specific retroviral restriction domain. 
Proc Natl Acad Sci USA. 2005;102:2832–7. doi:10.1073/pnas.0409853102.
 18. Han K, Lou DI, Sawyer SL. Identification of a genomic reservoir for new 
TRIM genes in primate genomes. PLoS Genet. 2011;7(12):e1002388. 
doi:10.1371/journal.pgen.1002388.
 19. Goldschmidt V, Ciuffi A, Ortiz M, Brawand D, Munoz M, Kaessmann H, 
et al. Antiretroviral activity of ancestral TRIM5alpha. J Virol. 2008;82:2089–
96. doi:10.1128/JVI.01828-07.
 20. Johnson WE, Sawyer SL. Molecular evolution of the antiretroviral TRIM5 
gene. Immunogenetics. 2009;61(3):163–76. doi:10.1007/s00251-009-0358-y.
 21. Qi CF, Bonhomme F, Buckler-White A, Buckler C, Orth A, Lander MR, et al. 
Molecular phylogeny of Fv1. Mamm Genome. 1998;9(12):1049–55.
 22. Stoye JP. Studies of endogenous retroviruses reveal a continuing 
evolutionary saga. Nat Rev Microbiol. 2012;10(6):395–406. doi:10.1038/
nrmicro2783.
 23. Chan E, Schaller T, Eddaoudi A, Zhan H, Tan CP, Jacobsen M, et al. Lenti-
viral gene therapy against human immunodeficiency virus type 1, using 
a novel human TRIM21-cyclophilin A restriction factor. Hum Gene Ther. 
2012;23(11):1176–85. doi:10.1089/hum.2012.083.
 24. Chan E, Towers GJ, Qasim W. Gene therapy strategies to exploit TRIM 
derived restriction factors against HIV-1. Viruses. 2014;6(1):243–63. 
doi:10.3390/v6010243.
 25. Lilly F. Fv-2: identification and location of a second gene governing the 
spleen focus response to Friend leukemia virus in mice. J Natl Cancer Inst. 
1970;45:163–9.
 26. Hartley JW, Rowe WP, Huebner RJ. Host-range restrictions of murine 
leukemia viruses in mouse embryo cell cultures. J Virol. 1970;5:221–5.
 27. Rowe WP. Studies of genetic transmission of murine leukemia 
virus by AKR mice. I. Crosses with Fv-1 n strains of mice. J Exp Med. 
1972;136:1272–85.
 28. Rowe WP, Hartley JW. Studies of genetic transmission of murine leukemia 
virus by AKR mice. II. Crosses with Fv-1 b strains of mice. J Exp Med. 
1972;136:1286–301.
 29. Hartley JW, Rowe WP, Huebner RJ. Host-range restrictions of murine 
leukemia viruses in mouse embryo cell cultures. J Virol. 1970;5(2):221–5.
 30. Hopkins N, Schindler J, Hynes R. Six-NB-tropic murine leukemia viruses 
derived from a B-tropic virus of BALB/c have altered p30. J Virol. 
1977;21(1):309–18.
 31. Rommelaere J, Donis-Keller H, Hopkins N. RNA sequencing provides evi-
dence for allelism of determinants of the N-, B- or NB-tropism of murine 
leukemia viruses. Cell. 1979;16(1):43–50.
 32. Kozak CA, Chakraborti A. Single amino acid changes in the murine leuke-
mia virus capsid protein gene define the target of Fv1 resistance. Virology. 
1996;225(2):300–5. doi:10.1006/viro.1996.0604.
 33. Jolicoeur P, Baltimore D. Effect of Fv-1 gene product on proviral DNA 
formation and integration in cells infected with murine leukemia viruses. 
Proc Natl Acad Sci USA. 1976;73:2236–40.
 34. Sveda MM, Soeiro R. Host restriction of Friend leukemia virus: synthesis 
and integration of the provirus. Proc Natl Acad Sci USA. 1976;73:2356–60.
 35. Sanz-Ramos M, Stoye JP. Capsid-binding retrovirus restriction factors: 
discovery, restriction specificity and implications for the development 
of novel therapeutics. J Gen Virol. 2013;94(Pt 12):2587–98. doi:10.1099/
vir.0.058180-0.
 36. Bishop KN, Mortuza GB, Howell S, Yap MW, Stoye JP, Taylor IA. Characteri-
zation of an amino-terminal dimerization domain from retroviral restric-
tion factor Fv1. J Virol. 2006;80:8225–35. doi:10.1128/JVI.00395-06.
 37. Goldstone DC, Walker PA, Calder LJ, Coombs PJ, Kirkpatrick J, Ball NJ, 
et al. Structural studies of postentry restriction factors reveal antiparal-
lel dimers that enable avid binding to the HIV-1 capsid lattice. Proc Natl 
Acad Sci USA. 2014. doi:10.1073/pnas.1402448111.
 38. Best S, Le Tissier P, Towers G, Stoye JP. Positional cloning of the 
mouse retrovirus restriction gene Fv1. Nature. 1996;382:826–9. 
doi:10.1038/382826a0.
 39. Yap MW, Stoye JP. Intracellular localisation of Fv1. Virology. 
2003;307:76–89.
 40. Duran-Troise G, Bassin RH, Rein A, Gerwin BI. Loss of Fv-1 restriction in 
Balb/3T3 cells following infection with a single N tropic murine leukemia 
particle. Cell. 1977;10:479–88.
 41. Haran-Ghera N, Peled A, Brightman BK, Fan H. Lymphomagenesis in 
AKR.Fv-1b congenic mice. Cancer Res. 1993;53:3433–8.
 42. Lander MR, Chattopadhyay SK. A Mus dunni cell line that lacks sequences 
closely related to endogenous murine leukemia viruses and can be 
infected by ectropic, amphotropic, xenotropic, and mink cell focus-form-
ing viruses. J Virol. 1984;52:695–8.
 43. Jang SK, Krausslich HG, Nicklin MJ, Duke GM, Palmenberg AC, Wimmer E. 
A segment of the 5′ nontranslated region of encephalomyocarditis virus 
RNA directs internal entry of ribosomes during in vitro translation. J Virol. 
1988;62(8):2636–43.
 44. Benit L, De Parseval N, Casella JF, Callebaut I, Cordonnier A, Heidmann 
T. Cloning of a new murine endogenous retrovirus, MuERV-L, with 
strong similarity to the human HERV-L element and with a gag 
coding sequence closely related to the Fv1 restriction gene. J Virol. 
1997;71:5652–7.
Page 17 of 17Li et al. Retrovirology  (2016) 13:42 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 45. Zhou X, Vink M, Klaver B, Berkhout B, Das AT. Optimization of the Tet-On 
system for regulated gene expression through viral evolution. Gene Ther. 
2006;13(19):1382–90. doi:10.1038/sj.gt.3302780.
 46. Loew R, Heinz N, Hampf M, Bujard H, Gossen M. Improved Tet-responsive 
promoters with minimized background expression. BMC Biotechnol. 
2010;10:81. doi:10.1186/1472-6750-10-81.
 47. Pluta K, Luce MJ, Bao L, Agha-Mohammadi S, Reiser J. Tight control of 
transgene expression by lentivirus vectors containing second-generation 
tetracycline-responsive promoters. J Gene Med. 2005;7(6):803–17. 
doi:10.1002/jgm.712.
 48. Mizuguchi H, Xu Z, Ishii-Watabe A, Uchida E, Hayakawa T. IRES-dependent 
second gene expression is significantly lower than cap-dependent 
first gene expression in a bicistronic vector. Mol Ther. 2000;1(4):376–82. 
doi:10.1006/mthe.2000.0050.
 49. Bochkov YA, Palmenberg AC. Translational efficiency of EMCV IRES in 
bicistronic vectors is dependent upon IRES sequence and gene location. 
Biotechniques. 2006;41(3):283–4.
 50. Kozak M. Point mutations define a sequence flanking the AUG initia-
tor codon that modulates translation by eukaryotic ribosomes. Cell. 
1986;44(2):283–92.
 51. Hinnebusch AG, Jackson BM, Mueller PP. Evidence for regulation of reini-
tiation in translational control of GCN4 mRNA. Proc Natl Acad Sci USA. 
1988;85(19):7279–83.
 52. Jin X, Turcott E, Englehardt S, Mize GJ, Morris DR. The two upstream 
open reading frames of oncogene mdm2 have different translational 
regulatory properties. J Biol Chem. 2003;278(28):25716–21. doi:10.1074/
jbc.M300316200.
 53. Kozak M. Pushing the limits of the scanning mechanism for initiation of 
translation. Gene. 2002;299(1–2):1–34.
 54. Yan Y, Kozak CA. Novel postentry resistance to AKV ecotropic mouse 
gammaretroviruses in the African pygmy mouse, Mus minutoides. J Virol. 
2008;82(13):6120–9. doi:10.1128/JVI.00202-08.
 55. Rulli SJ Jr, Mirro J, Hill SA, Lloyd P, Gorelick RJ, Coffin JM, et al. Interac-
tions of murine APOBEC3 and human APOBEC3G with murine leukemia 
viruses. J Virol. 2008;82(13):6566–75. doi:10.1128/JVI.01357-07.
 56. Lilly F, Pincus T. Genetic control of murine viral leukemogenesis. Adv 
Cancer Res. 1973.
 57. Yap MW, Nisole S, Lynch C, Stoye JP. Trim5alpha protein restricts 
both HIV-1 and murine leukemia virus. Proc Natl Acad Sci USA. 
2004;101:10786–91. doi:10.1073/pnas.0402876101.
 58. Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, Fuss JO, et al. A 
versatile viral system for expression and depletion of proteins in mamma-
lian cells. PLoS One. 2009;4(8):e6529. doi:10.1371/journal.pone.0006529.
 59. Goldstone DC, Yap MW, Robertson LE, Haire LF, Taylor WR, Katzourakis A, 
et al. Structural and functional analysis of prehistoric lentiviruses uncov-
ers an ancient molecular interface. Cell Host Microbe. 2010;8:248–59. 
doi:10.1016/j.chom.2010.08.006.
 60. Yap MW, Lindemann D, Stanke N, Reh J, Westphal D, Hanenberg H, et al. 
Restriction of foamy viruses by primate Trim5alpha. J Virol. 2008;82:5429–
39. doi:10.1128/JVI.02462-07.
